First Western Trust Bank Has $1.75 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

First Western Trust Bank increased its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 3.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,816 shares of the biopharmaceutical company’s stock after acquiring an additional 1,221 shares during the period. First Western Trust Bank’s holdings in Bristol-Myers Squibb were worth $1,750,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Bahl & Gaynor Inc. raised its position in Bristol-Myers Squibb by 2.7% in the 1st quarter. Bahl & Gaynor Inc. now owns 44,568 shares of the biopharmaceutical company’s stock valued at $2,417,000 after buying an additional 1,183 shares during the last quarter. UniSuper Management Pty Ltd grew its stake in shares of Bristol-Myers Squibb by 15.1% during the 1st quarter. UniSuper Management Pty Ltd now owns 215,898 shares of the biopharmaceutical company’s stock worth $11,708,000 after acquiring an additional 28,373 shares in the last quarter. Delta Asset Management LLC TN raised its holdings in shares of Bristol-Myers Squibb by 11.5% in the first quarter. Delta Asset Management LLC TN now owns 86,361 shares of the biopharmaceutical company’s stock valued at $4,683,000 after purchasing an additional 8,897 shares during the last quarter. Bessemer Group Inc. lifted its position in shares of Bristol-Myers Squibb by 16.3% in the first quarter. Bessemer Group Inc. now owns 159,066 shares of the biopharmaceutical company’s stock worth $8,625,000 after purchasing an additional 22,286 shares in the last quarter. Finally, Lake Street Advisors Group LLC boosted its holdings in Bristol-Myers Squibb by 54.7% during the first quarter. Lake Street Advisors Group LLC now owns 13,530 shares of the biopharmaceutical company’s stock worth $734,000 after purchasing an additional 4,784 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on BMY. TD Cowen boosted their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Cantor Fitzgerald reissued a “neutral” rating and set a $50.00 price target on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. Sanford C. Bernstein started coverage on Bristol-Myers Squibb in a research report on Thursday, October 17th. They set a “market perform” rating and a $56.00 price target on the stock. Morgan Stanley increased their price objective on Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. Finally, Citigroup boosted their target price on shares of Bristol-Myers Squibb from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, two have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $54.07.

Insider Activity

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the sale, the senior vice president now owns 11,760 shares of the company’s stock, valued at $654,091.20. The trade was a 5.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Samit Hirawat bought 1,830 shares of the stock in a transaction dated Friday, November 1st. The shares were acquired at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the acquisition, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. This trade represents a 3.04 % increase in their position. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Stock Down 3.9 %

Shares of BMY opened at $56.22 on Monday. The firm’s 50-day simple moving average is $52.73 and its 200 day simple moving average is $47.27. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. The firm has a market cap of $114.02 billion, a P/E ratio of -15.66, a price-to-earnings-growth ratio of 15.23 and a beta of 0.44. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.08.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.49 by $0.31. The company had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.00 earnings per share. On average, analysts forecast that Bristol-Myers Squibb will post 0.93 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.27%. The ex-dividend date was Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is currently -66.85%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.